Focus on Follicular Lymphoma


Welcome to Focus on FL

The FocusOnFL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by follicular lymphoma (FL).
 
We invite you to browse the website to learn more about follicular lymphoma and the resources offered by the Lymphoma Research Foundation.
 
About the Lymphoma Research Foundation
 

Our Mission

The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. LRF's mission is to eradicate lymphoma and serve those touched by this disease.
 

Our Founders

LRF was formed in November 2001 by the merger of the Cure for Lymphoma Foundation (CLF) and the Lymphoma Research Foundation of America (LRFA). Both organizations were founded by lymphoma advocates who sought to use their personal experiences with lymphoma to benefit others with the disease. CLF was founded in 1994 in New York City by Jerry Freundlich, a non-Hodgkin lymphoma survivor, and his wife Barbara Freundlich. LRFA was founded in 1991 by Ellen Glesby Cohen, who lost her own battle with non-Hodgkin lymphoma in August 2000. 
 
 
 
LRF National Headquarters | Wall Street Plaza, 88 Pine Street, Suite 2400 | New York, NY 10005 | 212-349-2910 | 212-349-2886 Fax | LRF@lymphoma.org
 
LRF Helpline | 800-500-9976 | Helpline@lymphoma.org
 

About Follicular Lymphoma

 
Lymphoma is the most common form of blood cancer. There are two main forms of lymphoma: non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Lymphoma occurs when lymphocytes - a type of white blood cell - grow abnormally. The body has two main types of lymphocytes that can develop into lymphomas: B-lymphocytes (B-cells) and T-lymphocytes (T-cells). These cancerous lymphocytes can travel to different parts of the body, including the lymph nodes, spleen, bone marrow, blood or other organs, and can accumulate to form tumors.
 
Follicular lymphoma is typically a slow-growing form of NHL that arises from B-lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 percent to 30 percent of all NHL cases.
 
Follicular lymphoma is usually not considered to be curable, but patients can live for many years with this form of lymphoma. It is a disease characterized by multiple relapses after responses to a variety of therapies.
 

Patient Programs and Services

 
The goal of the Lymphoma Research Foundation (LRF) is to assist everyone whose life has been affected by a lymphoma diagnosis. The Foundation is dedicated to raising public awareness of the disease and providing education and support to people with Follicular Lymphoma, their loved ones and caregivers.
 
LRF assists people with Follicular Lymphoma by providing comprehensive, disease-specific programs and services including:
 
  • Clinical Trials Information Service
  • Disease-Specific Publications and Websites
  • In-person Workshops and Educational Forums
  • Lymphoma Helpline
  • Lymphoma Support Network
  • Online Resources, Teleconferences and Webcasts/Podcasts
  • Patient Aid Grants
  • Professional Education
  • Public Policy and Advocacy Program
  • Volunteer Chapter Network

Follicular Lymphoma: Treatment Options

 
Treatment options for people with Follicular Lymphoma depend on the severity of associated symptoms as well as the rate of the cancer's growth. Only 10 to 20 percent of patients present with early stage follicular lymphoma (stages I and II), which is often treated with radiation (high-energy x-rays targeted at specific groups of involved lymph nodes). Radiation can provide a cure in some patients with limited disease. In more advanced stages, physicians may often use a single agent, immunotherapy or chemo-immunotherapy to treat the disease. Unlike many cancers, Follicular Lymphoma tends to be very sensitive to both radiation and chemotherapy. As such, numerous drugs, combinations of drugs, and treatment regimens can be used to manage follicular lymphoma.